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Introduction
N
on-alcoholic  fatty  liver  disease  (NAFLD) 
is very common and affects up to 24 % of 
the general population in various countries (1). An 
increased level of fatty acids within the hepatocytes 
causing oxidative stress, is believed to be responsible 
for the progression from steatosis to steatohepatitis 
and  cirrhosis.  The  elevated  serum  levels  of  liver 
enzymes may be the only laboratory clues during this 
progress (2). 
Studies focus on anti-oxidative material in order 
to find protection against liver injury. Vitamins C 
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Background and Aims:  Non-alcoholic fatty liver change is a common disease of the liver in which oxidative stress plays 
a basic role. Studies are largely focused on protecting the liver by means of anti-oxidative material. The aim of this study 
is to evaluate the role of N- acetylcysteine in the process of liver injury.
Methods: Thirty patients with non-alcoholic fatty liver steatosis were randomly selected to receive either N-acetylcysteine 
or vitamin C. Liver function tests (alanine aminotransfrase, aspartate aminotransfrase and alkaline phosphatase) were 
measured as well as the grade of steatosis, the pattern of its echogenicity, the span of the liver and the spleen and the 
portal vein diameter before the intervention. Patients were followed up using the same method of evaluation repeated 
in the first, second and third months. 
Results: The mean age (SD) was 40.1(12.4) in patients receiving NAC and 46(10.4) years in patients receiving vitamin 
C (P = 0.137). NAC resulted in a significant decrease of serum alanine aminotransfrase after three months, compared 
to vitamin C. This effect was independent of the grade of steatosis in the initial diagnosis. NAC was able to significantly 
decrease the span of the spleen.
Conclusions: N-acetylcysteine can improve liver function in patients with non-alcoholic fatty liver disease. Better results 
may be achievable in a longer follow up.
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and E have been found to have both protective and 
therapeutic effects on NAFLD in an animal model 
(3, 4). This effect has been linked to the anti-oxidative 
function  of  these  two  vitamins.  Nevertheless  no 
medication  has  been  definitively  established  for 
NAFLD and research has tried different free-radical 
scavengers and antioxidant agents.
N-acetylcysteine  (NAC)  is  frequently  utilized 
where  intracellular  oxidant-antioxidant  balance  is 
concerned.  NAC  has  a  protective  effect  against 
liver  injury  in  rats  (5-8).  One  study  has  reported 
improvement of liver histopathology and reduction 
of oxidative stress by NAC in non-alcoholic fatty 
steatosis (NASH) in a rat model (9). A recent study has 
reported a significant decrease in liver steatosis and 
fibrosis in patients with NASH receiving Metformin 
and  NAC  (10).  In  this  study,  the  significance  of 
treatment with NAC in patients with NAFLD and 
with elevated liver enzymes has been investigated.
Materials and methods
This study was carried out in the clinics of Tabriz 
University of Medical Sciences during 2008 and the 
protocols were approved by the Ethical Committee 
of this University. 
Patients  with  ongoing  NAFLD  were  included 
in this study and received either NAC (600 mg per 
12 hours) or vitamin C (1000 mg per 12 hours). 
Patients with a diagnosis of NAFLD are commonly 
registered  in  this  clinic.  Patients  would  pick  up  a 
ticket from a box containing mixed labels of two 
different  treatments,  twenty  from  each  category. 
Data collection was stopped when fifteen patients 
completed  the  treatment  and  the  follow-up 
procedures. 
Most  of  the  patients  were  referred  because 
of elevated liver enzymes or a report of fatty liver 
in  sonographic  evaluation  and  some  had  non-
specific complaints like abdominal discomfort. All 
patients gave their written consent. Patients received 
medication for medical conditions if necessary.
The  results  of  the  clinical  examination,  the 
elevated level of liver enzymes, an ultrasonographic 
study of the liver and the exclusion of other etiologies 
for liver disease were the basis for the diagnosis of 
NAFLD. A detailed history was taken and patients 
with a history of alcohol consumption or the use 
of medications known to precipitate steatohepatitis, 
lipid-reducing  agents,  ursodeoxycholic  acid  or 
vitamin supplements in the 6 months prior to study 
were excluded. 
Laboratory evaluation in this study included serum 
liver  tests:  aspartate  transaminase  (AST),  alanine 
transaminase (ALT), and alkaline phosphatase (ALP). 
Further  investigations  included  a  hepatobiliary-
system  ultrasound,  viral  serology,  autoantibody 
titers, serum iron, ferritin and transferrin saturation, 
ceruloplasmin and urine copper levels. Serological 
tests for hepatitis B, the antibody to the hepatitis 
C virus or autoantibodies, i.e., antinuclear antibody 
(ANA), antimitochondrial antibodies (AMA), anti-
smooth muscle antibody (ASMA), and antibodies to 
liver-kidney microsome (anti-LKM), were negative 
in all patients. Serum electrolytes, urea, creatinine, 
fasting glucose, complete blood count, cholesterol 
and triglyceride levels were also obtained. An ion 
profile,  α1-antitripsine  and  serum  ceruloplasmin 
levels were normal in all patients. 
Serum  biochemistry  and  ultrasonographic 
measurement  of  the  liver  and  the  spleen  were 
performed at entry and every month for the period 
of  the  study.  Liver  hemodynamics,  the  grade  of 
steatosis and the size of the spleen were measured 
by the same radiologist, blinded to the treatment 
method of the patients. 
All data were expressed as the mean ± standard 
deviation  (SD).  A  chi-squared  test  was  used  to 
compare  qualitative  variables  and  Student’s  t-test 
was used to compare quantitative variables between 
the  two  groups  of  patients.  A  repeated-measures 
ANOVA and k-related-samples tests were used to 
compare the data before and during each treatment 
where appropriate. A P-value of 0.05 was considered 
statistically significant. 
Results
Fifteen patients completed the study procedure 
and were available for a full follow-up in each group 
as described above. The study population included 6 
males and 9 females treated with NAC and 5 males 
and 10 females treated with vitamin C. No adverse 
drug effects were reported during the study. 
The initial characteristics of the study population 
is described in Table 1.These two randomly selected 
groups were well matched as to body mass index 
(BMI),  diabetes  or  hyperlipidemia,  which  was 
Table 1: The comparison between the two study groups 
regarding age and aspects of metabolic syndrome.
NAC (n=15) Vitamin C (n=15) P
Mean age (SD) 40.1(12.4) 46.8(1.4) 0.137
Body mass index 30.3(5.0) 33.2(6.7) 0.201
Diabetes mellitus no(%) 1(6.7) 2(13.3) 0.534
Hyperlipidemia no(%)  2(13.3) 1(6.7) 0.534
Hypertension  1(6.7) 1(6.7) 1.000Hepatitis Monthly, Winter 2010; 10(1): 12-16
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no significant change was observed in the grade of 
steatosis of the liver.
Conclusions
The current study described the effectiveness of 
a three-month consumption of NAC in patients with 
NAFLD, which resulted in a decrease in the level 
of ALT and in the size of the spleen, compared to 
those patients taking vitamin C. To our knowledge, 
few studies have been carried out to examine the 
implication of NAC on liver function in patients with 
NAFLD, and in particular on liver hemodynamics. 
  Macrovesicular  steatosis  in  the  absence  of 
significant  alcohol  consumption  is  the  main 
characteristic  of  NAFLD,  as  a  spectrum  of  liver 
diseases.  This  condition  may  be  a  precursor  of 
NASH which has been found to lead to progressive 
fibrosis and cirrhosis. Impaired cellular function has 
contributed  to  oxidative  stress  leading  to  cellular 
death and hepatic necrosis caused by free radicals 
(11, 12). This impaired cellular function can be traced 
by liver function tests, which may even be the only 
indicator, up until the point of serious liver damage. 
Antioxidant  supplements  may  protect  cellular 
structures against oxidative stress. Such studies have 
been  carried  out  by  investigating  the  therapeutic 
interventions  for  NAFLD  and  NASH  against 
oxidative  stresses,  but  so  far  there  has  been  no 
consensus about the therapeutic benefits (13). The 
present  study  evaluates  the  therapeutic  effect  of 
NAC on patients with NAFLD compared to Vitamin 
C, as well as, for the first time, on hemodynamic 
parameters.
The ability of NAC to block the propagation of 
lipid peroxidation is reflected in the prevention of the 
onset of NAFLD by means of oral administration 
of S-nitroso-N-acetylcysteine in rats (14) and in the 
improvement of liver histology in rats with NASH 
after NAC treatment (9) However, the dietary addition 
of NAC is reported to have the same effect as diet 
alone and can improve the liver histopathology of 
NASH (15).
The clinical features of NASH and NAFLD are 
very similar, and there is no non-invasive tool for 
a definite diagnosis. We have tried to compensate 
for the nonattendance for a liver biopsy (for ethical 
reasons) by selecting patients with NAFLD who had 
elevated liver enzymes in order to obtain a sample 
more similar to that found in patients with NASH. 
Such  a  condition  is  believed  to  have  a  clinically 
significant risk of developing end-stage liver disease 
(16). 
NAC can only decrease the serum level of ALT. 
The relationship between ALT and NAFLD has not 
been  completely  explained,  but  studies  support  a 
higher level of ALT as not only a consequence but 
also a predictor of the development of NASH in 
these patients (17). Thus decreasing the level of ALT 
may be the best effect that it is possible to achieve.
The present study has evaluated the effects of 
antioxidants  on  ultrasonographic  features  of  liver 
function for the first time. Fatty change in the liver 
means enlargement of the hepatocytes containing 
fat  droplets.  This  slows  down  the  blood  flow 
throughout  the  hepatic  sinusoids  and  may  result 
in  the  development  of  portal  hypertension.  A 
correlation has been noted between the degree of 
fatty infiltration in the liver, and the size of spleen 
(18). The current study suggests a decrease in the size 
of the spleen in NAFLD patients receiving NAC, 
which may reflect a reduction in fatty infiltration. 
These effects of NAC can be evaluated in detail by 
reviewing liver specimens after the intervention, and 
may be improved after a longer duration.
In  conclusion,  a  three-month  supplement  of 
NAC can alter ALT and the size of the spleen in 
patients with NAFLD, which is compatible with the 
improvement of fatty infiltration as has been shown 
in earlier studies.
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